Evidence map›Paper›PMID 26098791›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2015

Interactions between amino acid-defined major histocompatibility complex class II variants and smoking in seropositive rheumatoid arthritis.

Kwangwoo Kim, Xia Jiang, Jing Cui, Bing Lu, Karen H Costenbader, Jeffrey A Sparks, So-Young Bang, Hye-Soon Lee, Yukinori Okada, Soumya Raychaudhuri and 4 more

Abstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Global epidemiology of rheumatoid arthritis.Nature reviews. Rheumatology · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Current research status of HLA in immune-related diseases.Immunity, inflammation and disease · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 5 countries.

Kwangwoo KimHanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, and Broad Institute, Cambridge, Massachusetts.
Xia JiangKarolinska Institute, Stockholm, Sweden.
Jing CuiBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, and Broad Institute, Cambridge, Massachusetts.
Bing LuBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Karen H CostenbaderBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Jeffrey A SparksBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
So-Young BangHanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea.
Hye-Soon LeeHanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea.
Yukinori OkadaBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, Broad Institute, Cambridge, Massachusetts, Tokyo Medical and Dental University, Tokyo, Japan, and RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Soumya RaychaudhuriBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, Broad Institute, Cambridge, Massachusetts, and Manchester Academic Health Sciences Centre, Manchester, UK.
Lars AlfredssonKarolinska Institute, Stockholm, Sweden.
Sang-Cheol BaeHanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea.
Lars KlareskogKarolinska Institutet and Karolinska Hospital, Stockholm, Sweden.
Elizabeth W KarlsonBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Harvard University · USBrigham and Women's Hospital · USKarolinska Institutet · SEHanyang University · KRHanyang University Seoul Hospital · KRManchester Academic Health Science Centre · GB

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2000 to 2019
$77.8M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Life Course Cancer Epidemiology Cohort in WomenUM1CA176726 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2013 to 2017
$15.7M
Premonopausal Hormone Levels and Risk of Breast CancerR01CA067262 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HANKINSON, SUSAN E · 2002 to 2011
$11.9M
BIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORTR01CA049449 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E · 1989 to 2008
$11.3M
Novel Biomarkers and Prediction Models for Rheumatoid ArthritisR01AR049880 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI COSTENBADER, KAREN H, KARLSON, ELIZABETH W · 2003 to 2018
$8.7M
Genetic predictors of response to anti-TNF therapy in rheumatoid arthritisU01GM092691 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI BRENNER, MICHAEL B., RAYCHAUDHURI, SOUMYA · 2010 to 2014
$7.5M
Discovery and Functional Impact of Common and Rare Variants in RAR01AR063759 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Soumya Raychaudhuri · 2013 to 2026
$5.4M
BIOCHEMICAL MARKERS IN THE NURSES HEALTH STUDY COHORTU01CA049449 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI HANKINSON, SUSAN E · 1995 to 2013
$5.4M
Functional Genomics of PsoriasisR01AR065183 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ELDER, JAMES TILFORD · 2013 to 2016
$1.7M
Novel Biomarkers and Causal Pathways in RA SusceptbilityR01AR059073 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI COSTENBADER, KAREN H · 2010 to 2013
$1.5M
Genetic Predictors of Early Atherosclerosis in SLEK24AR052403 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI KARLSON, ELIZABETH W · 2005 to 2014
$1.5M
NCI NIH HHS CA-176726NCI NIH HHS CA-186107NCI NIH HHS CA-49449NCI NIH HHS CA-67262NCI NIH HHS P01 CA087969NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA067262NCI NIH HHS U01 CA049449NCI NIH HHS U01 CA067262NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA186107NIAMS NIH HHS AR-049880NIAMS NIH HHS AR-052403NIAMS NIH HHS AR-059073NIAMS NIH HHS K24 AR052403NIAMS NIH HHS L30 AR066953NIAMS NIH HHS R01 AR049880NIAMS NIH HHS R01 AR059073NIAMS NIH HHS R01 AR063759NIAMS NIH HHS R01-AR-063759-01A1NIAMS NIH HHS R01 AR065183NIAMS NIH HHS R01-AR-065183-01NIGMS NIH HHS U01 GM092691NIGMS NIH HHS U01-GM-092691-04
6 · The paper itself

Abstract

objectiveTo define the interaction between cigarette smoking and HLA polymorphisms in seropositive rheumatoid arthritis (RA), in the context of a recently identified amino acid-based HLA model for RA susceptibility.

methodsWe imputed Immunochip data on HLA amino acids and classical alleles from 3 case-control studies (the Swedish Epidemiological Investigation of Rheumatoid Arthritis [EIRA] study [1,654 cases and 1,934 controls], the Nurses' Health Study [NHS] [229 cases and 360 controls], and the Korean RA Cohort Study [1,390 cases and 735 controls]). We examined the interaction effects of heavy smoking (>10 pack-years) and the genetic risk score (GRS) of multiple RA-associated amino acid positions (positions 11, 13, 71, and 74 in HLA-DRβ1, position 9 in HLA-B, and position 9 in HLA-DPβ1), as well as the interaction effects of heavy smoking and the GRS of HLA-DRβ1 4-amino acid haplotypes (assessed via attributable proportion due to interaction [AP] using the additive interaction model).

resultsHeavy smoking and all investigated HLA amino acid positions and haplotypes were associated with RA susceptibility in the 3 populations. In the interaction analysis, we found a significant deviation from the expected additive joint effect between heavy smoking and the HLA-DRβ1 4-amino acid haplotype (AP 0.416, 0.467, and 0.796, in the EIRA, NHS, and Korean studies, respectively). We further identified the key interacting variants as being located at HLA-DRβ1 amino acid positions 11 and 13 but not at any of the other RA risk-associated amino acid positions. For residues in positions 11 and 13, there were similar patterns between RA risk effects and interaction effects.

conclusionOur findings of significant gene-environment interaction effects indicate that a physical interaction between citrullinated autoantigens produced by smoking and HLA-DR molecules is characterized by the HLA-DRβ1 4-amino acid haplotype, primarily by positions 11 and 13.

Indexed as

AdultAllelesAmino AcidsCase-Control StudiesFemaleGenes, MHC Class IIGenetic Predisposition to DiseaseGenetic VariationHaplotypesHLA-B AntigensHLA-DP beta-ChainsHLA-DRB1 ChainsHumansMaleMiddle AgedModels, GeneticAmino AcidsHLA-B AntigensHLA-DPB1 antigenHLA-DP beta-ChainsHLA-DRB1 Chains

Identifiers

PMID26098791
PMCPMC4581918
OpenAlexW2099911518

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.